Company intelligence / Profile preview

Skinbiotix

Manchester, Greater Manchester, United Kingdom

Ownership: Private
Employees: ~25
Development stage: Other

Overview

SkinBioTherapeutics is a life science company focused on harnessing the power of the microbiome to improve skin health. The company's proprietary SkinBiotix platform uses lysates derived from probiotic bacteria to enhance the skin's barrier function, protect against infection, and promote repair. Their lead commercial product, AxisBiotix-Ps, is a food supplement designed to manage the symptoms of psoriasis via the gut-skin axis. The company is also developing applications for eczema, acne, and anti-aging, while expanding its portfolio through strategic acquisitions like Dermatonics and Bio-Me.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Microbial therapyLive biotherapeutic product therapyProtein
Industry: Biotech

Partnerships

Croda InternationalSedermaWinclove Probiotics

Beyond the preview

Go deeper on Skinbiotix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skinbiotix.

Explore the full profile